## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- (Currently Amended) A method of stimulating an immune response, said method comprising administering a composition comprising an isolated polypeptide comprising an amino acid sequence having at least 98% identity to the entirety of residues 8 to 598 of SEQ ID NO: 140, and thereby stimulating an immune response specific for the polypeptide of residues 8 to 598 of SEQ ID NO: 140.
- 2. (Previously Presented) The method of claim 1, wherein the composition further comprises a physiologically acceptable carrier.
- (Previously Presented) The method of claim 1, wherein the composition further comprises an adjuvant.
- (Previously Presented) The method of claim 3, wherein the adjuvant induces an immune response predominantly of the Th1 type.
- (Previously Presented) The method of claim 4, wherein the adjuvant is selected from the group consisting of monophosphoryl lipid A, 3-de-O-acylated monophosphoryl lipid A, CpG-containing oligonucleotides, saponins, QS21, and combinations thereof.
- (Previously Presented) The method of claim 3, wherein the adjuvant is an aminoalkyl glucosaminide 4-phosphate.
- (Previously Presented) The method of claim 6, wherein the aminoalkyl glucosaminide 4-phosphate is RC-529.
- (Currently Amended) The method of claim 1, wherein the composition comprises residues 8 to 598 of the polypeptide of SEQ ID NO: 140.